Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04952597 · ClinicalTrials.gov registry record · Phase 2
Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer
A Phase 2 study, sponsored by BeiGene.
- Completed
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
NCT04952597: Completed Phase 2 study, sponsored by BeiGene.
NCT04952597 is a Phase 2 study that has completed, run by BeiGene. The registered enrollment target is 126 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04952597, a Phase 2 study, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
Study Summary
This phase 2 trial examined whether the preliminary efficacy and safety of ociperlimab, tislelizumab, and cCRT when used in combination is expected to advance treatment options in the serious unmet medical need population of Limited-Stage Small Cell Lung Cancer (LS-SCLC) participants .
Primary Outcome
Defined as the time from the date of randomization to the date of the first documented disease progression as determined by the investigator per RECIST v1.1 or death from any cause (whichever occurs first)
Interventions
- DRUG Tislelizumab
- DRUG Ociperlimab
- DRUG Concurrent Chemoradiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2021-07-15 |
| Est. Completion | 2023-07-26 |
| Phase | Phase 2 |
What the finished NCT04952597 record still lists
NCT04952597 is an interventional study that assigns participants to a tested intervention. The registered 126 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Tislelizumab is the first listed.
NCT04952597 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04952597 about?
NCT04952597 is a clinical study titled "Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer". This phase 2 trial examined whether the preliminary efficacy and safety of ociperlimab, tislelizumab, and cCRT when used in combination is expected to advance treatment options in the serious unmet medical need population of Limited-Stage Small Cell Lung Cancer (LS-SCLC) participants .
What is the current status of trial NCT04952597?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2021-07-15. Estimated completion is 2023-07-26.
What interventions are being tested in trial NCT04952597?
The interventions under investigation include: Tislelizumab (DRUG), Ociperlimab (DRUG), Concurrent Chemoradiotherapy (DRUG).
Who is sponsoring clinical trial NCT04952597?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04952597's enrollment target sits among peer trials
126 556th of 2000 higher than 1,443 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01873131 · 126 participants · NA
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- NCT02621645 · 126 participants · Phase 4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
- NCT03838107 · 126 participants
Markers of Trajectory in Pediatric CRPS
- NCT03906422 · 126 participants · NA
Comparison of Patient-reported Pain After Initial Archwire Placement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI